Commercial-stage biotechnology company Krystal Biotech Inc (NASDAQ:KRYS) announced on Tuesday that the US Food and Drug Administration (FDA) has granted Fast Track designation for inhaled KB707 to treat solid tumours with pulmonary metastases that are relapsed or refractory to standard therapy.
KB707, a modified HSV-1 vector designed to deliver interleukin-12 and interleukin-2 genes to the tumour microenvironment, aims to promote immune-mediated tumour clearance.
In January 2024 the FDA cleared the Investigational New Drug (IND) application for Phase 1 clinical trial KYANITE-1, set to commence in the first half of 2024, targeting patients with locally advanced or metastatic solid tumours of the lung.
This is the second Fast Track for KB707, following the FDA's previous approval for intratumoral KB707 in melanoma treatment.
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
ArkBio commences Phase II clinical trial of AK0610
BioDlink makes first international shipment of bevacizumab to Colombia
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Merck reports long-term survival benefits of Keytruda in non-small cell lung cancer
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Sichuan Kelun-Biotech presents positive Phase 3 trial results for sac-TMT
SOPHiA DDM Digital Twins launched to simulate patient outcomes and support oncology decisions